Tian medicine shares: obtain the Serekib capsule drug registration certificate

On January 6, Tian Pharmaceutical Co., Ltd. announced that its subsidiary Tianjin Jinyao Pharmaceutical Co., Ltd. had recently received a "Drug Registration Certificate" on the specifications of 0.1g and 0.2g of Selesib capsules approved by the State Drug Administration.
celexib is a nonsteroidal anti-inflammatory drug that inhibits prostatin production by inhibiting cyclooxidase-2 (COX-2) to achieve anti-inflammatory, analgesic and dehealination effects.
capsules are used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and have fewer gastrointestinal side effects than traditional nonsteroidal anti-inflammatory drugs.
Jinyao Pharmaceuticals submitted to the State Drug Administration, the application for the registration of domestic drugs for Celesib capsules was accepted in September 2018, and recently obtained the "Drug Registration Certificate."
, Jinyao Pharmaceuticals has invested about 19 million yuan in research and development projects in the domestic declaration of Selesibu capsules.
。